CN116916955A - 减少人类受试者中的Tau的方法 - Google Patents

减少人类受试者中的Tau的方法 Download PDF

Info

Publication number
CN116916955A
CN116916955A CN202180087530.2A CN202180087530A CN116916955A CN 116916955 A CN116916955 A CN 116916955A CN 202180087530 A CN202180087530 A CN 202180087530A CN 116916955 A CN116916955 A CN 116916955A
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
chain variable
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180087530.2A
Other languages
English (en)
Chinese (zh)
Inventor
W·R·加尔彭
M·蒂默斯
T·L·K·雅各布斯
P·南迪
L·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN116916955A publication Critical patent/CN116916955A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202180087530.2A 2020-10-26 2021-10-25 减少人类受试者中的Tau的方法 Pending CN116916955A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105804P 2020-10-26 2020-10-26
US63/105804 2020-10-26
PCT/EP2021/079543 WO2022090158A1 (en) 2020-10-26 2021-10-25 Methods of reducing tau in human subjects

Publications (1)

Publication Number Publication Date
CN116916955A true CN116916955A (zh) 2023-10-20

Family

ID=78402146

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180087530.2A Pending CN116916955A (zh) 2020-10-26 2021-10-25 减少人类受试者中的Tau的方法

Country Status (11)

Country Link
US (1) US20220127345A1 (https=)
EP (1) EP4232155A1 (https=)
JP (1) JP2023546504A (https=)
KR (1) KR20230093499A (https=)
CN (1) CN116916955A (https=)
AU (1) AU2021367878A1 (https=)
CA (1) CA3199806A1 (https=)
IL (1) IL302386A (https=)
MX (1) MX2023004831A (https=)
TW (1) TW202233666A (https=)
WO (1) WO2022090158A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
JP7379764B1 (ja) 2022-08-09 2023-11-15 レール・リキード－ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード 空気分離装置および空気分離方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP6214161B2 (ja) * 2009-12-21 2017-10-18 ジェネンテック， インコーポレイテッド 抗体製剤
ITMI20120814A1 (it) * 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
CN117820467A (zh) * 2016-12-07 2024-04-05 基因泰克公司 抗tau抗体和使用方法
TWI771389B (zh) * 2017-03-16 2022-07-21 美商健生生物科技公司 抗phf-tau抗體及其用途
MA53338A (fr) * 2018-03-05 2022-01-05 Janssen Pharmaceutica Nv Dosages pour détecter la neurodégénérescence
WO2020223279A1 (en) * 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. VECTORIZED ANTIBODIES (vAb) AND USES THEREOF
EP4232472A1 (en) * 2020-10-26 2023-08-30 JANSSEN Pharmaceutica NV Method of safe administration of anti-tau antibody

Also Published As

Publication number Publication date
MX2023004831A (es) 2023-07-12
TW202233666A (zh) 2022-09-01
US20220127345A1 (en) 2022-04-28
KR20230093499A (ko) 2023-06-27
IL302386A (en) 2023-06-01
CA3199806A1 (en) 2022-05-05
AU2021367878A1 (en) 2023-06-22
JP2023546504A (ja) 2023-11-02
EP4232155A1 (en) 2023-08-30
WO2022090158A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
TW201946931A (zh) 人類化抗-tau抗體
CN106163548A (zh) 治疗阿尔茨海默氏病的方法
CN116916955A (zh) 减少人类受试者中的Tau的方法
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
TWI894689B (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
US20230391859A1 (en) Anti-transthyretin antibodies and methods of use thereof
US20250051427A1 (en) Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody
HK40100364A (zh) 减少人类受试者中的tau的方法
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
EA050381B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
CN116829582A (zh) 安全施用抗Tau抗体的方法
HK40100358A (zh) 安全施用抗tau抗体的方法
EA051320B1 (ru) Способ безопасного введения антитела к тау-белку
CN118450905A (zh) 使用抗淀粉样蛋白β初原纤维抗体和抗τ蛋白抗体的方法
TWI916375B (zh) 軸突損傷之預防
EA052963B1 (ru) Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40100364

Country of ref document: HK